Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. - Wikidata - awgldk - TriplyDB

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

http://www.wikidata.org/entity/Q33759715

about

Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer Regulatory Roles of MAPK Phosphatases in Cancer The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors Negative feedback regulation of the ERK1/2 MAPK pathway Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1 Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis Dynamic functional modulation of CD4+ T cell recall responses is dependent on the inflammatory environment of the secondary stimulus.Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells.Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.Selective activation of p53-mediated tumour suppression in high-grade tumours.MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease EGFR-mutated lung cancer: a paradigm of molecular oncology.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization.Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.Dual Specificity Phosphatase 5, a Specific Negative Regulator of ERK Signaling, Is Induced by Serum Response Factor and Elk-1 Transcription Factor EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.Research Resource: A Reference Transcriptome for Constitutive Androstane Receptor and Pregnane X Receptor Xenobiotic Signaling Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma.Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals virus-specific regulation of immune response genes.PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.Why are epididymal tumours so rare?RAF265 inhibits the growth of advanced human melanoma tumors.Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells ΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis.RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition.LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer The dual-specificity MAP kinase phosphatases: critical roles in development and cancer.Mitogen-Activated Protein (MAP) Kinase Scaffolding Proteins: A Recount.Mechanisms of RAS/β-catenin interactions.

P2860

Q21195199-0DCB5CCD-4E67-4418-AF79-5C594CBC607B Q26751025-367017A3-076B-4A16-8C40-7A181933F020 Q26770643-9195EA22-D360-4D23-86B3-FA9AC84796B7 Q27853211-5977D842-9A5F-40D4-B74C-D5636D96BB51 Q28079202-B6F5500B-CD94-4022-97B7-B65BFEED9E96 Q28116578-8CFD593D-ABA6-4C1C-B36C-B8952ED79D5B Q28655621-BEDD956C-2607-4450-9C79-B8D528CB3BDF Q30804219-38C2905A-A720-4BBA-A5BC-1032A8AAF0AC Q33650695-329629CF-DD86-484F-8842-2D6F9AAF782A Q34000677-AC05030F-A43E-4161-A06C-3FFE1253AE6B Q34074438-4210DF5E-63E1-4E33-A07D-41F3498A5DE7 Q34127155-A3BE0F72-65BE-41AC-9ECF-8694E31A93E2 Q34151826-320E0413-F9F1-47C8-915A-406E2C47D896 Q34324544-C5D77006-2564-4582-8DC4-E750C9E1D0A7 Q34406334-F56A64E5-EA23-47F4-B267-852B1A98E456 Q34465240-C2844DE6-3D32-40AF-8429-163124112D5E Q34518491-71944D2A-5FED-454E-8C0D-7186EAD7A45E Q34701196-5468ACB5-84D3-46D5-8697-2D48437E63D8 Q35022501-EB33187D-5D70-49C3-A0F6-048F547532F1 Q35134415-9403261D-038B-4662-8686-54D40A2785E4 Q35152542-85AC3876-A211-4306-8B41-DAD7EA2ECE76 Q35185157-6D31D381-C801-4136-BF60-4A1FE26540E4 Q35843618-971DCB56-30F9-4475-AFEE-B18F3FFAFC05 Q35874878-6D1B7A6D-1DE3-41D3-963F-E6708612C6CD Q35895556-3537CB9F-B1AC-44D8-B92A-ECE9ACC17D80 Q36030366-EFE3D6F2-D35D-43BF-888F-60C411424F56 Q36075002-4A3BE23F-5442-4472-AACD-2BB555D14A7D Q36439343-5EAD8740-406F-4931-805E-1AAE14784F4B Q36675323-DB8AA9F8-73EA-4D82-AE0D-58C82FA21E28 Q36688846-DF030DB5-6F75-481A-9FBD-1CC6DE95D7BC Q36740692-0C807373-D356-4D2A-9E2B-F3047C4B418E Q37037784-858A56CA-55D9-4CBB-A9E2-87E0DF00115E Q37047974-ACE8E44C-E5F3-411B-8E66-94D9897354C1 Q37215543-06DB0B89-6DEC-462D-8975-6C15744404F0 Q37656142-377F972C-CFC7-4A3C-A5FB-98118B2B0717 Q37672584-CCAD1A98-9BE9-4EB3-A49C-058D3521D349 Q37705948-FF054F21-F7C8-4006-A9DA-4F96FBF5B567 Q37750129-9FF44B7E-7B5D-4F29-A8B8-473CBC450D7C Q38086019-4D6892E4-BBB8-43EC-AA69-8AFF587DB579 Q38088654-25BB0021-68F2-488B-BB1E-85819B89C6B1

P2860

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

http://www.wikidata.org/entity/Q33759715

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@ast

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@en

type

label

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@ast

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@en

prefLabel

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@ast

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@en

P1433

Q33759715-B8EF3DBA-8CB7-4A32-A4A5-9CD9AA537A76

P1476

Q33759715-F61CB7D7-286E-47B4-9F1C-93249209A107

P2093

Q33759715-0035657A-865E-4F1E-8D44-6E5731F6FD17

Q33759715-8C4F5A64-BF33-4A06-A027-3E50A5E090CE

Q33759715-A79EBA4B-C620-4D6C-86A3-C32C187611AB

Q33759715-AD2A8A5C-6AC2-46BB-8374-12D246C66D9C

Q33759715-B58E770B-ACFE-42F8-8B89-834B07E77FFB

Q33759715-C9878D4E-7148-4033-A051-D692AAFCA036

Q33759715-CA7C12F7-1D8C-443D-AF29-E4C07895BF31

P2860

Q33759715-00AEC0A8-8787-41F2-BE8E-A3EE8FCA3180

Q33759715-0F188052-284B-4962-8A6B-BC297B425A87

Q33759715-12744FC2-B9BA-4733-9FC1-040F8A67D9BE

Q33759715-13522C9C-F57E-44BA-A656-6831A8B413C3

Q33759715-262657D4-5C19-4C61-88A4-851DF737C95B

Q33759715-27114EB2-10AE-4621-8D36-66319F7B08BF

Q33759715-28343926-7DD0-4FF4-A934-C4A235F3E920

Q33759715-2AD2C4C7-7FD3-43FD-8D5E-B54C7C9280E6

Q33759715-2B9BC2B8-0C96-407A-9EF3-7A1E42F73510

Q33759715-2D0AF7C8-EF1F-4712-8B6A-BE968F67C897

P304

Q33759715-5224E6EF-F917-4B85-8D02-19278A45803D

P31

Q33759715-1C011D56-AA7B-4969-A86D-5C663F7BDDF4

P356

Q33759715-E8EB859C-2F83-4381-9AAF-CAFF9DB01AC7

P407

Q33759715-5D72D2B0-C628-4177-B884-1ABCF2F78234

P433

Q33759715-9B09FF70-DAEA-4AEE-8850-EEC182E02FAF

P478

Q33759715-FBD8A64C-E106-4F35-9705-A3439B29B9BC

P577

Q33759715-B91FDA2B-3113-494F-9DBB-CAE65112BF22

P5875

Q33759715-7499EC86-84DA-492D-B9CC-D3394C41B8D0

P698

Q33759715-D33C754E-25C1-45FF-905F-45FE5D99A71C

P932

Q33759715-1BCB9370-4359-44F1-90E9-BC6CB695F7DB

P356

P1433

P1476

Dual specificity phosphatase 6 ...... ignaling in lung cancer cells.

@en

P2093

Alain C Borczuk

http://www.w3.org/2001/XMLSchema#string

Alan D Levine

http://www.w3.org/2001/XMLSchema#string

Balazs Halmos

http://www.w3.org/2001/XMLSchema#string

Rom S Leidner

http://www.w3.org/2001/XMLSchema#string

Susumu Kobayashi

http://www.w3.org/2001/XMLSchema#string

Thomas Laframboise

http://www.w3.org/2001/XMLSchema#string

Zhenfeng Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Isolation of the human genes encoding the pyst1 and Pyst2 phosphatases: characterisation of Pyst2 as a cytosolic dual-specificity MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases

MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Cancer statistics, 2008

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Abrogation of DUSP6 by hypermethylation in human pancreatic cancer

P304

577-586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGQ020

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41123121

http://www.w3.org/2001/XMLSchema#string

P698

20097731

http://www.w3.org/2001/XMLSchema#string

P932

2847094

http://www.w3.org/2001/XMLSchema#string